Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Early Phase 1
1(16.7%)
Phase 2
1(16.7%)
6Total
Phase 1(4)
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00111657Phase 2Completed

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

Role: lead

NCT00644514Phase 1Terminated

Genetics of Asthma - Bronchoscopy Studies

Role: lead

NCT00671593Phase 1Terminated

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge

Role: lead

NCT00643058Phase 1Terminated

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II

Role: lead

NCT00671892Phase 1Completed

Role of TLR4 in Environmental Asthma

Role: lead

NCT01385215Early Phase 1Completed

Strategies for Enhancing Mucosal Immunity to Influenza Vaccine

Role: lead

All 6 trials loaded